Fibrosis and progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

被引:98
|
作者
Norman, Jill [1 ]
机构
[1] UCL Med Sch, Div Med, UCL Ctr Nephrol, London NW3 2PF, England
关键词
Fibroblasts; Myofibroblasts; Fibrosis; Extracellular matrix; Epithelial-fibroblast interactions; Chronic kidney disease; ABNORMAL EXTRACELLULAR-MATRIX; GELATINASE-A MMP-2; MESENCHYMAL TRANSITION; CELL-PROLIFERATION; PKD1; GENE; INTERSTITIAL FIBROSIS; TARGETED DISRUPTION; TISSUE INHIBITOR; EPITHELIAL-CELLS; RENAL FIBROSIS;
D O I
10.1016/j.bbadis.2011.06.012
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The age on onset of decline in renal function and end-stage renal disease (ESRD) in autosomal polycystic kidney disease (ADPKD) is highly variable and there are currently no prognostic tools to identify patients who will progress rapidly to ESRD. In ADPKD, expansion of cysts and loss of renal function are associated with progressive fibrosis. Similar to the correlation between tubulointerstitial fibrosis and progression of chronic kidney disease (CKD), in ADPKD, fibrosis has been identified as the most significant manifestation associated with an increased rate of progression to ESRD. Fibrosis in CKD has been studied extensively. In contrast, little is known about the mechanisms underlying progressive scarring in ADPKD although some commonality may be anticipated. Current data suggest that fibrosis associated with ADPKD shares at least some of the "classical" features of fibrosis in CKD (increased interstitial collagens, changes in matrix metalloproteinases (MMPs), over-expression of tissue inhibitor of metalloproteinase-1 (TIMP-1), over-expression of plasminogen activator inhibitor-1 (PAI-1) and increased transforming growth factor beta (TGF beta) but that there are also some unique and stage-specific features. Epithelial changes appear to precede and to drive interstitial changes leading to the proposal that development of fibrosis in ADPKD is biphasic with alterations in cystic epithelia precipitating changes in interstitial fibroblasts and that reciprocal interactions between these cell types drives progressive accumulation of extracellular matrix (ECM). Since fibrosis is a major component of ADPKD it follows that preventing or slowing fibrosis should retard disease progression with obvious therapeutic benefits. The development of effective anti-fibrotic strategies in ADPKD is dependent on understanding the precise mechanisms underlying initiation and progression of fibrosis in ADPKD and the role of the intrinsic genetic defect in these processes. This article is part of a Special Issue entitled: Polycystic Kidney Disease. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:1327 / 1336
页数:10
相关论文
共 50 条
  • [31] Commentary: Tolvaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) - an update
    Gittus, Matt
    Haley, Helen
    Harris, Tess
    Borrows, Sarah
    Padmanabhan, Neal
    Gale, Danny
    Simms, Roslyn
    Williams, Terri
    Acquaye, Aaron
    Wong, Alisa
    Chan, Melanie
    Lee, Eduardo
    Ong, Albert C. M.
    BMC NEPHROLOGY, 2025, 26 (01)
  • [32] AUTOSOMAL-DOMINANT POLYCYSTIC KIDNEY-DISEASE (ADPKD) IN KOREA
    LEE, JG
    AHN, C
    HAN, JS
    KIM, SH
    GERMINO, GG
    KIM, S
    LEE, JS
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1994, 5 (03): : 648 - 648
  • [33] The Genetics of Vascular Complications in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Rossetti, Sandro
    Harris, Peter C.
    CURRENT HYPERTENSION REVIEWS, 2013, 9 (01) : 37 - 43
  • [34] Evidence for anticipation in autosomal-dominant polycystic kidney disease (ADPKD).
    Mazeau, P
    Boulahrouz, R
    Charasse, C
    Ang, KS
    LeCacheux, P
    Simon, P
    KIDNEY INTERNATIONAL, 1996, 50 (05) : 1777 - 1777
  • [35] Echocardiographic Abnormalities in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Patients
    Pfeferman, Mariana Becker
    da Rocha, Daniel Ribeiro
    Rodrigues, Fernanda Guedes
    Pfeferman, Elcio
    Heilberg, Ita Pfeferman
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (20)
  • [36] Role of apoptosis in the development of autosomal dominant polycystic kidney disease (ADPKD)
    Peintner, Lukas
    Borner, Christoph
    CELL AND TISSUE RESEARCH, 2017, 369 (01) : 27 - 39
  • [37] IMPACT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) ON CAREGIVERS AND FAMILIES
    Oberdhan, D.
    Cole, J. C.
    Palsgrove, A.
    VALUE IN HEALTH, 2018, 21 : S109 - S110
  • [38] Elevated proinflammatory chemokines in autosomal dominant polycystic kidney disease (ADPKD).
    Cowley, BD
    Ricardo, SD
    Diamond, JR
    JOURNAL OF INVESTIGATIVE MEDICINE, 1996, 44 (07) : A380 - A380
  • [39] Analysis of Calcium Signaling in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Van Giel, Dorien
    Decuypere, Jean-Paul
    Mekahli, Djalila
    Vennekens, Rudi
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 401 - 401
  • [40] THE BURDEN OF TOLVAPTAN TREATMENT FOR AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
    Muto, Satoru
    Kawano, Haruna
    Sugiura, Syou-ichiro
    Kitamura, Kousuke
    Kimura, Masaki
    Isotani, Shuji
    Ide, Hisamitsu
    Yamaguchi, Raizo
    Horie, Shigeo
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30